Bridge GLP compliant drug development in the US & China
Press Releases
< Return back to Press Releases
Bridge Announces $22 Million Series B Capital Raise June 12, 2006 - San Francisco, CA Bridge Laboratories, the leading preclinical Contract Research Organization in Asia, announced today that it has recently closed $22 million Series B round of financing. The investors were returning Series A investors and new venture and investment banking investors from the US. The capital raised will be used to fund development of its core business and provide for funds for future potential acquisitions in Asia. About Pharmaron Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com. |